Prithviraj Bose, MD
Cervantes F et al. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: The REALISE phase 2 study. Leukemia 2021;35(12):3455-65. Abstract
Gupta V et al. Safety and efficacy of fedratinib in patients with primary (P), post-polycythemia vera (post-PV), and post-essential thrombocythemia (post-ET) myelofibrosis (MF) previously treated with ruxolitinib: Primary analysis of the FREEDOM trial. ASH 2022;Abstract 1711.
Harrison C et al. Overall and progression-free survival in patients treated with fedratinib as first-line myelofibrosis (MF) therapy and after prior ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 trials. EHA 2021;Abstract S203.
Verstovsek S et al. Does early intervention in myelofibrosis impact outcomes? A pooled analysis of the COMFORT I and II studies. ASH 2021;Abstract 1505.
John Mascarenhas, MD
Mesa R et al. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia 2022;36(9):2261-8. Abstract
Oh ST et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 2023;bloodadvances.2023010151. Abstract
Oh ST et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. ASH 2022;Abstract 628.
Pemmaraju N et al. Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF). ASCO 2022;Abstract 7058.
Verstovsek S et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 2023;401(10373):269-80. Abstract
Andrew Kuykendall, MD
Ayala R et al. BMS-986158, a potent BET inhibitor, as monotherapy and in combination with ruxolitinib or fedratinib in intermediate- or high-risk myelofibrosis (MF): Results from a phase 1/2 study. EHA 2023;Abstract S213.
Gerds AT et al. Efficacy and safety of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study. EHA 2023;Abstract S167.
Harrison CN et al. Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: Phase II safety and efficacy. J Clin Oncol 2022;40(15):1671-80. Abstract
Harrison CN et al. Phase III MANIFEST-2: Pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future Oncol 2022;18(27):2987-97. Abstract
Mascarenhas J et al. MANIFEST: Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve myelofibrosis. J Clin Oncol 2023;[Online ahead of print]. Abstract
Passamonti F et al. The combination of navitoclax and ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis mediates responses suggestive of disease modification. ASH 2022;Abstract.
Scandura J et al. Clinical benefit associated with biomarker changes indicative of disease modification in patients with myelofibrosis treated with the BET inhibitor pelabresib as monotherapy or in combination with ruxolitinib. ASH 2022;Abstract.